Anticancer Drugs Market is estimated to reach a whopping valuation of US$ 227 Bn by the end of 2026, up from just under US$ 129 Bn in 2018. This is indicative of a growth rate of 7.4% during the period from 2018 to 2026.

Anticancer Drug Market Outlook

The global anticancer drug market size was valued at approximately $150 billion in 2023 and is projected to reach around $280 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.2% during the forecast period. This growth is primarily driven by the increasing prevalence of various types of cancers, advancements in drug development technologies, and a growing emphasis on personalized medicine. The rising incidence of cancer globally is fueling the demand for more effective and targeted anticancer therapies. Moreover, supportive government policies and increasing healthcare expenditure in developed as well as emerging economies are propelling the market forward.

One of the significant growth factors for the anticancer drug market is the advancements in biotechnology and pharmaceutical research that have led to the development of targeted therapies and biologics. These treatments offer a more personalized approach to cancer care, showing higher efficacy and fewer side effects compared to traditional chemotherapy. The pharmaceutical industry is investing heavily in research and development to introduce innovative drugs that target specific cancer cells while minimizing harm to healthy cells. This shift towards precision medicine is a crucial driver of market growth, as it holds the promise of improved survival rates and better quality of life for cancer patients.

Furthermore, the increasing prevalence of cancer worldwide is a major factor contributing to the growth of the anticancer drug market. Lifestyle changes, aging populations, and environmental factors are leading to a higher incidence of cancer, necessitating effective treatment options. Governments and healthcare organizations are implementing various awareness programs and screening initiatives to facilitate early diagnosis and treatment, which in turn boosts the demand for anticancer drugs. The availability of advanced diagnostic tools and technologies also supports the early detection of cancer, thereby increasing the chances of successful treatment outcomes and further driving market expansion.

Another crucial factor fostering growth in the anticancer drug market is the rise of strategic collaborations and partnerships among pharmaceutical companies. By pooling resources and expertise, companies are able to accelerate drug development processes and expand their product portfolios. These collaborations often lead to the discovery and commercialization of novel therapeutics, thereby enhancing market competitiveness and growth. Additionally, mergers and acquisitions are prevalent in this sector, enabling companies to expand their geographic presence and technological capabilities, which further supports market growth.

Anti-Neoplastic Agents play a crucial role in the fight against cancer, serving as a cornerstone in the development of modern anticancer therapies. These agents are specifically designed to inhibit the growth and spread of malignant cells, thereby providing a targeted approach to cancer treatment. As research in oncology advances, the efficacy and specificity of Anti-Neoplastic Agents continue to improve, offering hope for more effective and less toxic treatment options. The integration of these agents into treatment regimens has been pivotal in enhancing patient outcomes, particularly in cases where traditional therapies have proven inadequate. With ongoing innovations, Anti-Neoplastic Agents are expected to further revolutionize cancer care, contributing significantly to the anticipated growth of the anticancer drug market.

Regionally, North America remains a dominant player in the anticancer drug market, owing to its well-established healthcare infrastructure, high investment in cancer research, and the presence of major pharmaceutical companies. However, the Asia Pacific region is expected to exhibit significant growth during the forecast period, driven by increasing healthcare expenditure, a rising prevalence of cancer, and growing awareness about cancer treatment options. Additionally, improving healthcare facilities and government initiatives to enhance cancer care infrastructure in countries such as India and China are anticipated to bolster the market in this region. Europe and Latin America are also expected to show moderate growth due to similar drivers, while the Middle East & Africa region faces challenges but is gradually progressing with improved healthcare access.

Drug Type Analysis

The anticancer drug market

The global oncology (anti-cancer drugs) market is experiencing robust growth, driven by several key factors. The rising incidence of cancer globally, coupled with an aging population in many developed nations, significantly contributes to the market expansion. Advances in cancer treatment, particularly in targeted therapies, immunotherapies (including biologic therapies), and the development of novel drug combinations, are leading to improved patient outcomes and increased demand for these therapies. While chemotherapy remains a significant segment, the market is witnessing a shift towards more targeted and less toxic treatment options, with immunotherapy showing particularly strong growth. The market segmentation reveals significant opportunities across various cancer types, with blood cancer, breast cancer, and gastrointestinal cancer currently dominating. However, the increasing prevalence of other cancers, along with ongoing research and development efforts, promises future growth across all segments. The competitive landscape is characterized by the presence of major pharmaceutical companies heavily invested in oncology research and development, leading to continuous innovation and the introduction of new therapies. Geographic variations exist, with North America and Europe currently holding significant market shares due to high healthcare expenditure and advanced healthcare infrastructure. However, emerging markets in Asia-Pacific and other regions are expected to show substantial growth in the coming years driven by rising healthcare awareness and investment in healthcare infrastructure. Further fueling this market expansion is the ongoing research into personalized medicine, which aims to tailor treatment approaches based on individual patient genetics and tumor profiles. This personalized approach promises improved efficacy and reduced side effects, thereby increasing the overall market value. Despite the positive outlook, the market faces challenges including high drug costs, stringent regulatory approvals, and the development of drug resistance. Nevertheless, the overall trend indicates a sustained and substantial rise in the global oncology drug market throughout the forecast period, with consistent year-on-year growth. The presence of established pharmaceutical giants coupled with investment in promising biotechnological advances ensures continuous market development and expansion across various therapeutic areas. The strategic partnerships and mergers within the sector further solidify this trend, creating a highly dynamic and evolving landscape.

Oncology Anti-Cancer Drugs Market Outlook

The global oncology anti-cancer drugs market size was valued at approximately USD 150 billion in 2023 and is projected to reach USD 300 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.5% during the forecast period. The growth of this market is driven primarily by the increasing global incidence of cancer, advancements in drug development technologies, and a growing focus on personalized medicine. The rising awareness and adoption of cancer screening programs across the world are also contributing significantly to the heightened demand for effective anti-cancer drugs.

One of the primary growth factors driving the oncology anti-cancer drugs market is the increasing burden of cancer worldwide. According to the World Health Organization, cancer is one of the leading causes of death globally, with millions of new cases diagnosed each year. This alarming rise in cancer prevalence has led to a greater demand for innovative and effective treatment options, thereby fueling the market's growth. Additionally, the aging global population, which is more susceptible to various forms of cancer, further accentuates the need for advanced therapeutic solutions, propelling the market forward.

Another significant growth factor is the rapid advancements in biopharmaceutical technologies. The progression from traditional chemotherapy to more sophisticated targeted therapies and immunotherapies has revolutionized cancer treatment paradigms. Targeted therapies, which focus on specific molecular targets associated with cancer, offer higher efficacy and reduced side effects compared to conventional treatments. Similarly, immunotherapies that harness the body's immune system to fight cancer have shown promising results in improving patient outcomes. These technological advancements have not only expanded the range of available treatments but also spurred research and development investments, contributing to market growth.

The growing emphasis on personalized medicine is also playing a crucial role in the expansion of the oncology anti-cancer drugs market. Personalized medicine involves tailoring medical treatment to the individual characteristics of each patient, which is particularly beneficial in cancer treatment. The advent of genomic sequencing and biomarker-based therapies has enabled healthcare providers to choose the most effective treatment regimens based on a patient's genetic makeup. This approach not only improves treatment efficacy but also minimizes adverse effects, leading to higher adoption rates and boosting market growth.

The role of Cancer Biopharmaceuticals in the oncology anti-cancer drugs market cannot be overstated. These biopharmaceuticals, which include monoclonal antibodies, therapeutic proteins, and vaccines, have transformed the landscape of cancer treatment. By leveraging biological molecules, cancer biopharmaceuticals offer targeted approaches that can specifically attack cancer cells while sparing healthy tissues, thus reducing the adverse side effects typically associated with traditional chemotherapy. The development of these biopharmaceuticals is driven by cutting-edge research in molecular biology and genetics, which allows for the creation of highly specific therapies tailored to the unique genetic profiles of individual tumors. As a result, cancer biopharmaceuticals are not only enhancing treatment efficacy but also paving the way for more personalized and effective cancer care.

Regionally, North America holds a significant share of the oncology anti-cancer drugs market, largely due to the high prevalence of cancer and the presence of well-established healthcare infrastructure. Moreover, the region benefits from substantial government funding for cancer research and development, alongside high patient awareness and access to innovative therapies. The Asia Pacific region is expected to exhibit the highest growth rate during the forecast period, driven by increasing healthcare expenditure, improving medical infrastructure, and rising cancer incidences in countries like China and India. Furthermore, the presence of a large patient pool and favorable government initiatives to support cancer treatment also contribute to the region's robust growth outlook.

Drug Type Analysis

The oncology anti-cancer drugs market is categorized by drug type into chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and others. Chemotherapy, one of the oldest form

Anti-Cancer Drug Market Outlook

The global anti-cancer drug market size was valued at approximately USD 150 billion in 2023 and is projected to reach nearly USD 330 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.2% during the forecast period. This substantial growth is driven by a multitude of factors, including advancements in cancer research, the increasing prevalence of various cancer types, and the rising demand for more effective and targeted therapies. As a result, the anti-cancer drug market is poised for significant expansion, fueled by both technological innovation and the pressing need to address the global cancer burden.

One of the primary growth factors for the anti-cancer drug market is the continuous advancement in biotechnology, which has ushered in a new era of personalized medicine. With a deeper understanding of cancer genomics, researchers are now able to develop targeted therapies that work specifically against cancer cell mutations, thereby increasing treatment efficacy while minimizing side effects. This precision-driven approach is significantly enhancing patient outcomes and is likely to continue propelling market growth. Furthermore, the approval of novel immune-oncology drugs, which harness the body's immune system to fight cancer, has opened new therapeutic avenues, further stimulating market dynamics.

Increasing cancer incidence worldwide is another pivotal growth driver for the anti-cancer drug market. With lifestyle changes, aging populations, and rising exposure to risk factors like smoking, pollution, and unhealthy diets, cancer prevalence has been on an upward trajectory. This surge in cancer cases is creating a heightened demand for effective treatment options, thereby driving the market for anti-cancer drugs. Governments and private organizations are investing heavily in cancer research and control programs, which is also contributing to the marketÂ’s expansion. Additionally, the growing awareness of cancer and its early detection is enabling more patients to seek timely treatment, thereby boosting the demand for anti-cancer medications.

The rise of strategic partnerships and collaborations between pharmaceutical companies and research institutes is also catalyzing growth in the anti-cancer drug market. These collaborations are leading to accelerated drug discovery and development processes, resulting in the introduction of innovative therapeutic solutions. The sharing of knowledge and resources is enhancing the ability to bring breakthrough treatments to market more efficiently. Moreover, the use of artificial intelligence and machine learning in drug development is optimizing clinical trials and expediting the approval process, thereby facilitating market growth. As a result, the anti-cancer drug market is likely to witness robust growth in the coming years.

Cancer Supportive Care Drugs play a crucial role in enhancing the quality of life for cancer patients undergoing treatment. These drugs are designed to alleviate the side effects associated with cancer therapies, such as nausea, pain, and fatigue, thereby improving patient compliance and overall treatment outcomes. As the demand for comprehensive cancer care grows, the market for supportive care drugs is expanding, driven by the need to address the holistic needs of patients. Pharmaceutical companies are increasingly focusing on developing innovative supportive care solutions that complement primary cancer treatments, ensuring that patients can maintain a better quality of life during their treatment journey.

From a regional perspective, North America currently dominates the anti-cancer drug market, attributed to its advanced healthcare infrastructure, high healthcare expenditure, and the presence of leading pharmaceutical companies. Europe follows closely, benefiting from strong government support for cancer research and a well-established healthcare system. The Asia Pacific region, however, is anticipated to witness the highest growth rate during the forecast period, driven by a large patient pool, increasing healthcare investments, and improved access to cancer treatments. Emerging markets in Latin America and the Middle East & Africa are also expected to contribute to the global market expansion, albeit at a slower pace, due to evolving healthcare landscapes and increasing awareness of cancer treatments.

Drug Type Analysis

Within the realm of anti-cancer drugs, chemotherapy remains one of the most established

Oncology/Cancer Drugs Market was valued at USD 156.61 Billion in 2023 and is projected to reach USD 265.69 Billion by 2031, growing at a CAGR of 6.83% during the forecast period 2024-2031.Oncology/Cancer Drugs Market: Definition/ OverviewOncology/Cancer Drugs are medications designed to treat cancer by inhibiting the growth of cancerous cells, preventing their spread, or alleviating symptoms. These drugs can be classified into several categories, including chemotherapy, targeted therapy, immunotherapy, hormone therapy, and others, each with distinct mechanisms of action.These drugs are used across different cancer types and stages, with chemotherapy often employed for its broad-spectrum efficacy, targeted therapies focusing on specific genetic markers, and immunotherapies enhancing the body's immune response against cancer. Hormone therapies are specifically used for hormone-sensitive cancers like breast and prostate cancer, while radiopharmaceuticals deliver radiation directly to cancer cells. Supportive care drugs are also essential for managing side effects and improving patients' quality of life during treatment.The future of oncology drugs is promising, with advancements in personalized medicine allowing for treatments tailored to individual genetic profiles, thereby improving efficacy and reducing toxicity. Cutting-edge immunotherapies, such as CAR-T cell therapy and checkpoint inhibitors, are expected to revolutionize cancer treatment.

Immuno-oncology Drugs Market size is growing with a CAGR of 18.6% in the prediction period and it crosses USD 106.74 Bn by 2032 from USD 32.32 Bn in 2025.

In 2022, the global market for cancer drugs was estimated at 147 billion U.S. dollars. By 2032, this market is forecasted to reach over 300 billion U.S. dollars. This statistic illustrates the size of the cancer drug market worldwide in 2022 and 2032.

Oncology Drugs Market size is estimated to be valued at USD 261.22 Bn in 2025 and is expected to expand at a CAGR of 12.8%, reaching USD 607.36 Bn by 2032.

The North America Oncology Anti-Cancer Drugs report provides a detailed analysis of emerging investment pockets, highlighting current and future market trends. It offers strategic insights into capital flows and market shifts, guiding investors toward growth opportunities in key industry segments and regions.

The US Oncology Drugs Market encompasses a wide range of products, each targeting specific types of cancer and treatment modalities. Chemotherapy drugs, which involve the use of cytotoxic agents to kill cancer cells, hold a significant market share. Targeted therapies, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, are gaining prominence due to their ability to inhibit specific molecular pathways involved in cancer growth. Immunotherapies, which stimulate the immune system to recognize and attack cancer cells, are also witnessing increasing adoption. Recent developments include: May 2023:AbbVie Inc. announced the U.S. FDA approval for its EPKINLY, among the only drugs for treating patients with relapsed or refractory diffuse large b-cell lymphoma (DLBCL)., March 2023:Pfizer Inc. announced a merger agreement to acquire Seagen, Inc., a global biotechnology company manufacturing cancer medicines. The acquisition would strengthen Pfizer's capabilities and expertise inoncology.. Key drivers for this market are: Rising prevalence of cancer Technological advancements leading to more effective therapies. Potential restraints include: High cost of cancer treatments Lack of access to healthcare in underserved areas. Notable trends are: Personalized treatments based on genetic profiling Combination therapies for improved efficacy.

The global anti-cancer drug market is a substantial and rapidly growing sector. While the provided data states a 2025 market size of $110,520 million (assuming "Value Unit million" refers to USD), the CAGR is missing. However, considering the continuous advancements in oncology research and the increasing prevalence of cancer globally, a conservative estimate for the CAGR over the forecast period (2025-2033) would be around 7-8%. This growth is fueled by several key drivers. The development of novel targeted therapies, immunotherapies, and personalized medicine approaches are significantly impacting treatment strategies and market expansion. Rising cancer incidence rates across major regions, coupled with increased healthcare expenditure and improved access to advanced medical facilities, particularly in developing economies, further contribute to market growth. While pricing pressures and stringent regulatory approvals pose challenges, the overwhelming demand for effective cancer treatments is expected to outweigh these restraints, leading to robust market expansion. The market segmentation highlights the dominance of key drugs like Avastin, Rituxan, Herceptin, and Alimta, indicating the significance of targeted therapies. The application segment shows a spread across hospitals, clinics, and home care settings, reflecting the evolving landscape of cancer treatment delivery. Major pharmaceutical companies like Merck, Bristol-Myers Squibb, and Roche are key players, engaging in intense R&D and strategic collaborations to maintain their market leadership. Geographical distribution showcases North America and Europe as mature markets, but significant growth potential exists in Asia Pacific and other emerging economies due to rising cancer prevalence and improving healthcare infrastructure. This combined growth across segments and regions suggests the global anti-cancer drug market is poised for continued strong growth and significant innovation in the coming years. The forecast period (2025-2033) is projected to witness substantial market expansion, driven by the aforementioned factors.

Middle East and Africa Oncology Drug market size will be USD 4122.50 million in 2024 and will expand at a compound annual growth rate (CAGR) of 12.9% from 2024 to 2031.

With cancer being increasingly prevalent in the country, the market for antineoplastic drugs in China expanded significantly in recent years, with a market size of almost 200 billion yuan in 2020. The market size is expected to grow further over the coming years, to around 415 billion yuan in 2025.

Oncology Drugs Market Outlook

The global oncology drugs market size is projected to grow significantly, from USD 142.5 billion in 2023 to approximately USD 286.4 billion by 2032, reflecting a robust Compound Annual Growth Rate (CAGR) of 8.1% over the forecast period. This substantial growth can be attributed to several factors such as the rising prevalence of various types of cancer, advancements in drug development technologies, and increasing investment in healthcare infrastructure across the globe.

One of the primary growth factors for the oncology drugs market is the escalating incidence of cancer worldwide. According to the World Health Organization (WHO), cancer is one of the leading causes of death globally, accounting for millions of deaths each year. This alarming rise has led to increased demand for effective cancer treatments and medications, thereby propelling the growth of the oncology drugs market. Additionally, the growing awareness about early cancer detection and the importance of timely treatment is driving the demand for oncology drugs.

Another significant growth driver is the continuous advancements in medical technology and pharmaceutical research. The development of novel drug formulations, targeted therapies, and personalized medicine is revolutionizing cancer treatment. Targeted therapies, in particular, have shown promising results in improving patient outcomes by specifically targeting cancer cells while minimizing damage to healthy cells. These technological advancements are expected to fuel market growth over the forecast period.

Furthermore, increasing healthcare expenditure and government initiatives to improve cancer care are contributing to market expansion. Governments and healthcare organizations across the globe are investing heavily in cancer research and development, aiming to discover more effective treatments and drugs. Moreover, various public and private sector initiatives to enhance healthcare infrastructure and provide better access to cancer treatments are expected to bolster market growth.

From a regional perspective, North America holds a significant share in the global oncology drugs market, driven by high healthcare spending, advanced healthcare infrastructure, and robust R&D activities. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period, owing to the rising cancer prevalence, increasing healthcare awareness, and improving healthcare facilities in emerging economies such as China and India.

Drug Class Analysis

The oncology drugs market is segmented by drug class into cytotoxic drugs, targeted drugs, hormonal drugs, and others. Cytotoxic drugs, also known as chemotherapy, are designed to kill rapidly dividing cancer cells. Despite their widespread use, these drugs can also affect healthy cells, leading to various side effects. Nonetheless, cytotoxic drugs remain a cornerstone of cancer treatment, particularly for aggressive and advanced-stage cancers. The demand for cytotoxic drugs is expected to persist, driven by their efficacy in shrinking tumors and controlling cancer spread.

Targeted drugs represent a more recent advancement in cancer treatment and have gained significant traction due to their ability to specifically target cancer cells with minimal impact on normal cells. These drugs work by interfering with specific molecules involved in cancer cell growth and survival. As a result, targeted therapies often have fewer side effects compared to traditional chemotherapy. The demand for targeted drugs is anticipated to increase as more targeted therapies receive regulatory approval and become available in the market.

Hormonal drugs are primarily used in the treatment of hormone-sensitive cancers such as breast cancer and prostate cancer. These drugs work by blocking or lowering the levels of hormones that stimulate cancer cell growth. Hormonal therapies have been particularly effective in managing hormone receptor-positive cancers and are often used in combination with other treatments. The market for hormonal drugs is expected to grow steadily, driven by the increasing incidence of hormone-sensitive cancers and ongoing research in this area.

The "others" category includes a range of emerging therapies and experimental drugs that do not fit into the traditional categories of cytotoxic, targeted, or hormonal drugs. This segment is characterized by ongoing research and development efforts aimed at discovering novel treatments for various types of cancer. Immunotherapies,

Anti-cancer Drugs Market size was valued at USD 140.3 Billion in 2023 and is projected to reach USD 303.2 Billion by 2030, growing at a CAGR of 9.2% during the forecast period 2024-2030.

Global Anti-cancer Drugs Market Drivers

The market drivers for the Anti-cancer Drugs Market can be influenced by various factors. These may include:

Growing Incidence of Cancer: The market for anticancer medications is significantly influenced by the growing incidence of cancer throughout the globe. There is a growing need for efficient treatment alternatives as the frequency of different tumors keeps rising.

Progress in the Field of Research and Development: New medications and treatment modalities are discovered as a result of ongoing oncology research and development efforts. Targeted treatments and immunotherapies are developed in part due to advances in our understanding of cancer biology and molecular pathways.

Innovations in Technology: The creation of more effective and tailored anticancer medications is being fueled by technological developments in areas like precision oncology, personalized medicine, and genomics. This makes it possible to customize patient treatments based on their unique genetic and molecular traits.

Increasing Priority for Immunotherapy: Immunotherapy has come to light as a potentially effective cancer treatment strategy. Immunocheckpoint inhibitors and CAR-T cell treatments are two examples of medications that boost the body's immune response to target and destroy cancer cells. These medications are becoming more and more popular.

Spending More on Healthcare: The general rise in healthcare spending around the world, particularly in developing nations, makes cancer therapies more widely available. This covers the price of pharmaceuticals as well as related services and supportive care.

Partnerships & Cooperations: Research institutes, pharmaceutical corporations, and healthcare organizations working together is essential to the advancement of anticancer medication development. The sharing of resources, knowledge, and technologies is made easier by partnerships.

Governmental Programs and Assistance with Regulations: The market can be positively impacted by government initiatives and regulatory support, such as accelerated approval processes for novel cancer treatments. Investment in the field of oncology may also be influenced by incentives for research and development.

Patient Awareness and Advocacy: The demand for anticancer pharmaceuticals is influenced by increased knowledge about cancer, early identification, and the availability of cutting-edge treatment alternatives through patient advocacy groups and awareness campaigns.

The global anticancer drug market is a rapidly expanding sector, driven by increasing cancer incidence rates worldwide, an aging global population, and continuous advancements in cancer therapies. The market, estimated at $180 billion in 2025, is projected to experience robust growth, with a Compound Annual Growth Rate (CAGR) of approximately 7% from 2025 to 2033. This growth is fueled by the rising adoption of targeted therapies and immunotherapies, offering more precise and effective treatments with fewer side effects compared to traditional chemotherapy. Key segments driving market expansion include immunotherapy, which is showing remarkable success in treating various cancers, and targeted therapies, which are personalized to specific genetic mutations. The increasing prevalence of cancer types like lung, breast, and colorectal cancer further contributes to the market's growth trajectory. However, high drug costs, stringent regulatory approvals, and potential side effects associated with certain therapies pose challenges to market expansion. Despite these restraints, the market is expected to witness significant growth across all regions, with North America, Europe, and Asia Pacific leading the way due to advanced healthcare infrastructure, robust research and development activities, and high healthcare expenditure. Major pharmaceutical companies like Roche, Pfizer, Bristol-Myers Squibb, and Novartis are at the forefront of innovation, constantly developing and launching new anticancer drugs, fostering competition and driving further market expansion. The market segmentation across application (immunotherapy, targeted therapy, chemotherapy, hormonal therapy, others) and drug types (targeted drugs, cytotoxic drugs, hormonal drugs, others) reflects the diverse therapeutic approaches available and the ongoing research into novel treatment modalities. The future of the anticancer drug market is promising, with continued investment in research and development expected to deliver more effective and personalized treatments, thereby improving patient outcomes and driving further market growth over the forecast period.

The global oncology drugs market is set to record a market value of US$ 202.9 Bn in 2022 and expand at a CAGR of 5.5% to reach US$ 347.3 Bn by the end of 2032.

In 2020, antineoplastic drugs had a market size of almost 200 billion yuan in China. Despite its adverse side effects, chemotherapy remained one of the leading treatment methods of cancer, with chemotherapy drugs occupying almost two-thirds of the anticancer drug market in China. The market for targeted therapy and immunotherapy medications is expected to boom in the coming years, with new drugs developed and approved every year.

The oncology drugs market size was valued at USD 165.90 Billion in 2024, driven by the rising prevalence of personalised medicine across the major markets. The market is expected to grow at a CAGR of 13.20% during the forecast period of 2025-2034, with the values likely to rise from USD 187.8 billion in 2025 to USD 573.21 Billion by 2034.